Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Harpoon Therapeutics Inc's Business Segments
Harpoon Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 4
Regions Reported
-
Harpoon Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Collaboration and License100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration and License | $ 4 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Harpoon Therapeutics Inc
Harpoon Therapeutics Inc. is a clinical-stage immuno-oncology company based in South San Francisco, California. The company was founded in 2015 and is focused on developing novel T-cell engagers to harness the body's immune system in order to fight and eliminate cancer.
Harpoon's approach is centered around its proprietary Tri-specific T-cell Activating Construct (TriTAC) platform, which is designed to enable the specific engagement and activation of T cells against tumor cells. T cells are a type of white blood cell that play a critical role in the immune system's ability to detect and destroy abnormal cells, including cancer cells. By engaging and activating these T cells, Harpoon aims to enhance the immune response against cancer, leading to improved clinical outcomes.
The TriTAC platform utilizes a unique engineered protein format that can simultaneously bind to both T cells and tumor cells. This enables the efficient transfer of T-cell activity to tumor cells, resulting in their destruction. In addition, Harpoon's T-cell engagers have been engineered to increase potency and enhance specificity, minimizing off-target toxicities.
The company has developed a pipeline of TriTAC molecules targeting different cancer antigens. One of its lead product candidates is HPN424, which is being developed for the treatment of metastatic prostate cancer. HPN424 targets prostate-specific membrane antigen (PSMA), a protein that is highly expressed on the surface of prostate cancer cells. By engaging T cells and directing them towards PSMA-expressing tumor cells, HPN424 aims to selectively kill cancer cells while sparing healthy cells.
Another promising candidate in Harpoon's pipeline is HPN536, which targets mesothelin, a protein that is overexpressed in several solid tumors, including mesothelioma, ovarian cancer, and pancreatic cancer. Preclinical studies have shown that HPN536 can effectively redirect T cells to tumor cells expressing mesothelin, leading to tumor cell killing.
Harpoon has also entered into collaborations with pharmaceutical companies, including AbbVie, to develop TriTAC-based therapies against specific targets. These collaborations provide additional resources and expertise to accelerate the development and commercialization of Harpoon's pipeline candidates.
In terms of clinical development, Harpoon has initiated several Phase 1/2 clinical trials to evaluate the safety and efficacy of its TriTAC molecules in patients with various types of cancer. These trials are designed to establish the optimal dosing, safety profile, and preliminary evidence of anti-tumor activity.
Overall, Harpoon Therapeutics Inc. is a biotechnology company that is pioneering the development of T-cell engagers to enhance the immune response against cancer. With its TriTAC platform and promising pipeline of candidates, Harpoon aims to bring novel therapies to patients and make a meaningful impact in the field of immuno-oncology.
Harpoon's approach is centered around its proprietary Tri-specific T-cell Activating Construct (TriTAC) platform, which is designed to enable the specific engagement and activation of T cells against tumor cells. T cells are a type of white blood cell that play a critical role in the immune system's ability to detect and destroy abnormal cells, including cancer cells. By engaging and activating these T cells, Harpoon aims to enhance the immune response against cancer, leading to improved clinical outcomes.
The TriTAC platform utilizes a unique engineered protein format that can simultaneously bind to both T cells and tumor cells. This enables the efficient transfer of T-cell activity to tumor cells, resulting in their destruction. In addition, Harpoon's T-cell engagers have been engineered to increase potency and enhance specificity, minimizing off-target toxicities.
The company has developed a pipeline of TriTAC molecules targeting different cancer antigens. One of its lead product candidates is HPN424, which is being developed for the treatment of metastatic prostate cancer. HPN424 targets prostate-specific membrane antigen (PSMA), a protein that is highly expressed on the surface of prostate cancer cells. By engaging T cells and directing them towards PSMA-expressing tumor cells, HPN424 aims to selectively kill cancer cells while sparing healthy cells.
Another promising candidate in Harpoon's pipeline is HPN536, which targets mesothelin, a protein that is overexpressed in several solid tumors, including mesothelioma, ovarian cancer, and pancreatic cancer. Preclinical studies have shown that HPN536 can effectively redirect T cells to tumor cells expressing mesothelin, leading to tumor cell killing.
Harpoon has also entered into collaborations with pharmaceutical companies, including AbbVie, to develop TriTAC-based therapies against specific targets. These collaborations provide additional resources and expertise to accelerate the development and commercialization of Harpoon's pipeline candidates.
In terms of clinical development, Harpoon has initiated several Phase 1/2 clinical trials to evaluate the safety and efficacy of its TriTAC molecules in patients with various types of cancer. These trials are designed to establish the optimal dosing, safety profile, and preliminary evidence of anti-tumor activity.
Overall, Harpoon Therapeutics Inc. is a biotechnology company that is pioneering the development of T-cell engagers to enhance the immune response against cancer. With its TriTAC platform and promising pipeline of candidates, Harpoon aims to bring novel therapies to patients and make a meaningful impact in the field of immuno-oncology.
Harpoon Therapeutics Inc. is a biotechnology company specializing in the development of innovative therapeutic approaches, primarily focusing on targeted cancer therapies. The company utilizes its proprietary TriTAC-XR platform, which is designed to develop novel therapeutics that bind to specific tumor-associated antigens. This unique pharmaceutical technology enables the creation of bispecific and multispecific targeting agents that are optimized for pharmacokinetics and pharmacodynamics, allowing for more effective clinical application against various malignancies.
Key Segments:
1. Immuno-Oncology:
The primary segment where Harpoon Therapeutics is focused is immuno-oncology, which harnesses the body’s immune system to more effectively target and destroy cancer cells. The company is particularly interested in developing therapies that can elicit a robust immune response against specific tumors, aiming to improve overall survival rates for patients with cancer.
2. Targeted Therapies:
This segment involves the creation of targeted agents that are designed to interact with specific cancer markers, increasing the precision and efficacy of treatments while minimizing off-target effects. The use of bispecific technology allows for the targeting of different epitopes on cancer cells, enhancing therapeutic potential.
Products:
1. TriTAC-XR Platform:
This is the foundational technology of Harpoon Therapeutics, enabling the development of a new class of therapeutics. The TriTAC-XR platform offers several key advantages:
- Extended Half-Life: The platform is engineered to enhance pharmacokinetics, ensuring that the drug remains active in the system longer, which can improve dosing schedules and patient convenience.
- Multispecific Targeting: By allowing for the simultaneous targeting of multiple antigens, TriTAC-XR products might provide improved efficacy in complex tumor environments.
- Tailored Immune Modulation: The platform can be engineered to modulate immune responses specifically against the tumor cells, enhancing the overall therapeutic effect while limiting side effects.
2. Lead Product Candidates:
Harpoon Therapeutics is actively developing several lead product candidates based on the TriTAC-XR platform:
- HARP-1: Targeted for the treatment of various solid tumors, HARP-1 is designed to engage the body’s immune system more effectively against established cancer cells.
- HARP-2: This candidate is focused on a specific subset of hematologic malignancies, leveraging targeted therapy to improve the outcomes in patients with certain blood cancers.
3. Preclinical and Clinical Trials:
Harpoon maintains a robust pipeline of product candidates that are either in preclinical development or undergoing clinical trials. The detailed investigation of these products focuses on evaluating their safety, efficacy, and optimal dosing strategies.
Services:
1. Collaboration and Partnerships:
Harpoon Therapeutics engages in strategic collaborations with other biotechnology and pharmaceutical companies. These partnerships can facilitate the sharing of technology and resources, help in advancing product development, and provide additional funding avenues. By collaborating with organizations that might have complementary technologies or distribution capabilities, Harpoon can accelerate its growth and enhance the impact of its product candidates.
2. Contract Research and Development:
The company may also provide research and development services to other entities interested in the TriTAC technology for their therapeutic applications. This aspect may involve sharing knowledge, technology, and platforms for efficient therapeutic development tailored to specific needs or conditions.
3. Regulatory Support:
As part of its service offerings, Harpoon Therapeutics may aid in navigating the complex regulatory landscape surrounding biotechnology products. This could involve consultations to ensure compliance with healthcare regulations, assisting in the preparation of Investigational New Drug applications, or engaging with regulatory agencies to facilitate rapid advancement of clinical trials.
Conclusion:
Harpoon Therapeutics Inc. centers its offerings around innovative cancer therapies that leverage its cutting-edge TriTAC-XR platform. By focusing on targeted immuno-oncology and establishing a diverse product pipeline, along with partnerships and collaborative efforts, the company aims to redefine and improve the standard of care in cancer treatment. The precision of its products, combined with strategic collaborations, positions Harpoon as an important player in the biotechnology landscape dedicated to combatting cancer.
Key Segments:
1. Immuno-Oncology:
The primary segment where Harpoon Therapeutics is focused is immuno-oncology, which harnesses the body’s immune system to more effectively target and destroy cancer cells. The company is particularly interested in developing therapies that can elicit a robust immune response against specific tumors, aiming to improve overall survival rates for patients with cancer.
2. Targeted Therapies:
This segment involves the creation of targeted agents that are designed to interact with specific cancer markers, increasing the precision and efficacy of treatments while minimizing off-target effects. The use of bispecific technology allows for the targeting of different epitopes on cancer cells, enhancing therapeutic potential.
Products:
1. TriTAC-XR Platform:
This is the foundational technology of Harpoon Therapeutics, enabling the development of a new class of therapeutics. The TriTAC-XR platform offers several key advantages:
- Extended Half-Life: The platform is engineered to enhance pharmacokinetics, ensuring that the drug remains active in the system longer, which can improve dosing schedules and patient convenience.
- Multispecific Targeting: By allowing for the simultaneous targeting of multiple antigens, TriTAC-XR products might provide improved efficacy in complex tumor environments.
- Tailored Immune Modulation: The platform can be engineered to modulate immune responses specifically against the tumor cells, enhancing the overall therapeutic effect while limiting side effects.
2. Lead Product Candidates:
Harpoon Therapeutics is actively developing several lead product candidates based on the TriTAC-XR platform:
- HARP-1: Targeted for the treatment of various solid tumors, HARP-1 is designed to engage the body’s immune system more effectively against established cancer cells.
- HARP-2: This candidate is focused on a specific subset of hematologic malignancies, leveraging targeted therapy to improve the outcomes in patients with certain blood cancers.
3. Preclinical and Clinical Trials:
Harpoon maintains a robust pipeline of product candidates that are either in preclinical development or undergoing clinical trials. The detailed investigation of these products focuses on evaluating their safety, efficacy, and optimal dosing strategies.
Services:
1. Collaboration and Partnerships:
Harpoon Therapeutics engages in strategic collaborations with other biotechnology and pharmaceutical companies. These partnerships can facilitate the sharing of technology and resources, help in advancing product development, and provide additional funding avenues. By collaborating with organizations that might have complementary technologies or distribution capabilities, Harpoon can accelerate its growth and enhance the impact of its product candidates.
2. Contract Research and Development:
The company may also provide research and development services to other entities interested in the TriTAC technology for their therapeutic applications. This aspect may involve sharing knowledge, technology, and platforms for efficient therapeutic development tailored to specific needs or conditions.
3. Regulatory Support:
As part of its service offerings, Harpoon Therapeutics may aid in navigating the complex regulatory landscape surrounding biotechnology products. This could involve consultations to ensure compliance with healthcare regulations, assisting in the preparation of Investigational New Drug applications, or engaging with regulatory agencies to facilitate rapid advancement of clinical trials.
Conclusion:
Harpoon Therapeutics Inc. centers its offerings around innovative cancer therapies that leverage its cutting-edge TriTAC-XR platform. By focusing on targeted immuno-oncology and establishing a diverse product pipeline, along with partnerships and collaborative efforts, the company aims to redefine and improve the standard of care in cancer treatment. The precision of its products, combined with strategic collaborations, positions Harpoon as an important player in the biotechnology landscape dedicated to combatting cancer.